IGFL2 and nonpapillary renal cell carcinoma: ccRCC patients with high IGFL2-AS1 expression had worse OS (Overall Survival), DSS (Disease Specific Survival) and PFS (Progression Free Survival) than the corresponding counterparts (Fig. 6G).